Pluri company information, Employees & Contact Information

Pluristem Therapeutics Inc. Changes its Name to “Pluri GlobeNewswire

FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome BioInformant

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture Nasdaq

Peripheral arterial disease (PAD) – A challenging manifestation of atherosclerosis ScienceDirect.com

Pluristem reports topline results from Covid-19 therapy trial Clinical Trials Arena

NASA-partnered Pluristem crashes to Earth as it axes leading therapy Fierce Biotech

Independent Study Shows Use of PLX-PAD Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury | Newswise Newswise

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US Labiotech.eu

Pluristem stock soars to 52-week high, hits $6.63 Investing.com

Israeli COVID-19 treatment shows 100% survival rate - preliminary data The Jerusalem Post

Hedge Funds Nibbling On Pluristem Therapeutics Inc. (PSTI) Yahoo Finance

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform PR Newswire UK

FDA clears Pluristem radiation treatment for emergency use Reuters

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform GlobeNewswire

Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO BioInformant

Pluristem’s cell therapies head for orbit with NASA deal Fierce Biotech

Pluristem Receives Approval for Grant from the Israel GlobeNewswire

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use BioInformant

Pluristem Lands $27 Million in Non-Dilutive Funding for its Advanced-Stage Cell Therapies BioInformant

Pluristem Gets Accelerated Approval Pathways in Top 3 Healthcare Markets – U.S., Europe, Japan BioInformant

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents BioInformant

Umbilical cord stem cells have the potential to treat COVID-19 Open Access Government

Israel's Tnuva partners with Pluristem to develop cultured cell-based meat The Jerusalem Post

Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project drugdiscoverytrends.com

Former United Therapeutics CEO joins Pluristem strategic advisory board The Jerusalem Post

Israeli companies at NASDAQ want to bring lab-grown meat to the masses Jewish Telegraphic Agency

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome BioInformant

Phase II COVID-19 placenta cellular therapy trial to launch in Israel The Jerusalem Post

FDA approves Israel-developed stem cell ‘factory’ for research The Times of Israel

Pluristem Prices Firm Commitment Underwritten Public Offering Of 8 Mln. Units RTTNews

The Abraham Accords and Israel–UAE normalization | 05 The economic dimension Chatham House

Pluristem, United Therapeutics Ink Exclusive Out-license Deal - Quick Facts RTTNews

Cathie Wood’s ARK Invest Sells 194,000 Shares of Pluristem Therapeutics 24/7 Wall St.

Pluristem Therapeutics appointed to Stem Cell Partnering Series Advisory Board - quick facts RTTNews

N.J. hospital is 1st in U.S to try placenta therapy on critically ill coronavirus patient NJ.com

Pluristem Therapeutics obtains approval from Biotec Services for PLX-PAD - Quick Facts RTTNews

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Trial To Treat Peripheral Artery Disease With PLX-PAD RTTNews

Pluristem Files Patent Application for PLX-1 Technology Networks

Study: Placenta cells could reverse stroke damage The Times of Israel

Pluristem gets positive results from radiation treatment trials The Fiji Times